{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:40:59Z","timestamp":1781210459261,"version":"3.54.1"},"reference-count":73,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["OMICS: A Journal of Integrative Biology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) is a systemic disease that impacts multiple organ systems with a complex clinical presentation and outcomes that can vary from person to person and between populations. To optimize COVID-19 treatment outcomes, and in light of the availability of antiviral drugs, there is a need for greater attention to the field of theranostics, the fusion of therapeutics and diagnostics. Theranostics tests would be invaluable, we suggest in this expert review, so as to optimize the efficacy and safety of current and future antiviral drugs against COVID-19. Theranostics would also assist in the design and implementation of clinical trials with antiviral drug candidates. We discuss here theranostics considering drugs such as remdesivir, Paxlovid\u2122, and molnupiravir. All in all, we underscore that theranostics as a concept and practice is essential for efficient and safe health interventions against COVID-19 and other ecological crises in the 21st century.<\/jats:p>","DOI":"10.1089\/omi.2022.0151","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T11:22:20Z","timestamp":1672917740000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision\/Personalized Medicine"],"prefix":"10.1177","volume":"27","author":[{"given":"Ca\u00edque","family":"Man\u00f3chio","sequence":"first","affiliation":[{"name":"Departamento de Patologia, Gen\u00e9tica e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas e Naturais, Universidade Federal do Tri\u00e2ngulo Mineiro, Uberaba, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Torres-Loureiro","sequence":"additional","affiliation":[{"name":"Departamento de Patologia, Gen\u00e9tica e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas e Naturais, Universidade Federal do Tri\u00e2ngulo Mineiro, Uberaba, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana M.","family":"Scudeler","sequence":"additional","affiliation":[{"name":"Departamento de Patologia, Gen\u00e9tica e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas e Naturais, Universidade Federal do Tri\u00e2ngulo Mineiro, Uberaba, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Miwa","sequence":"additional","affiliation":[{"name":"Departamento de Patologia, Gen\u00e9tica e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas e Naturais, Universidade Federal do Tri\u00e2ngulo Mineiro, Uberaba, Brazil."},{"name":"Departamento de Gen\u00e9tica, Ecologia e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda C.","family":"Souza-Santos","sequence":"additional","affiliation":[{"name":"Departamento de Patologia, Gen\u00e9tica e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas e Naturais, Universidade Federal do Tri\u00e2ngulo Mineiro, Uberaba, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-3223","authenticated-orcid":false,"given":"Fernanda","family":"Rodrigues-Soares","sequence":"additional","affiliation":[{"name":"Departamento de Patologia, Gen\u00e9tica e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas e Naturais, Universidade Federal do Tri\u00e2ngulo Mineiro, Uberaba, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2022.0045"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008457"},{"key":"e_1_3_5_4_1","author":"Aronson JK","year":"2017","unstructured":"Aronson JK, , Ferner RE. Biomarkers\u2014A general review. Curr Protoc Pharmacol, 2017;76(1):9.23.1\u20139.23.17; doi: 10.1002\/CPPH.19","journal-title":"Curr Protoc Pharmacol"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa152"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00220-5"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2398"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857573"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_5_10_1","author":"Biswas M","year":"2022","unstructured":"Biswas M, , Sawajan N, , Rungrotmongkol T, et al. Pharmacogenetics and precision medicine approaches for the improvement of COVID-19 therapies. Front Pharmacol, 2022;13; doi: 10.3389\/FPHAR.2022.835136","journal-title":"Front Pharmacol"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1973"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104541"},{"key":"e_1_3_5_13_1","first-page":"8","article-title":"REMDESIVIR: Mecanismo de A\u00e7\u00e3o, Ensaios Cl\u00ednicos e Pedidos de Patentes Depositados No INPI","author":"Carestiato T","year":"2020","unstructured":"Carestiato T, , Weid I von der. REMDESIVIR: Mecanismo de A\u00e7\u00e3o, Ensaios Cl\u00ednicos e Pedidos de Patentes Depositados No INPI. Minist\u00e9rio Da Econ Inst Nac da Propr Ind, 2020; 8.","journal-title":"Minist\u00e9rio Da Econ Inst Nac da Propr Ind"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12692"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104961"},{"key":"e_1_3_5_16_1","unstructured":"EMA. Veklury (Remdesivir): EU Summary of Product Characteristics. 2020:1\u201356."},{"key":"e_1_3_5_17_1","unstructured":"EMA. COVID-19 Treatments: Authorised | European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/treatments-covid-19\/covid-19-treatments-authorised [Last accessed: November 29 2022]."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000801"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00278-0"},{"key":"e_1_3_5_20_1","unstructured":"FDA. Fact Sheet For Healthcare Providers: Emergency Use Authorization For Lagevrio\u2122 (Molnupiravir) Capsules Highlights of Emergency Use Authorization (EUA) These Highlights of the EUA Do Not Include All the Information Needed to Use LAGEVRIO under the EUA. Available from: https:\/\/www.fda.gov\/media\/155054\/download [Last accessed: November 29 2022]."},{"key":"e_1_3_5_21_1","author":"Feingold KR","year":"2022","unstructured":"Feingold KR, , Anawalt B, , Boyce A, et al. Lipid and lipoprotein levels in patients with COVID-19 infections. Endotext, 2022.","journal-title":"Endotext"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15060739"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2015.70"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13030413"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110691"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0753-1"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa310"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283385a1c"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001191"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7"},{"issue":"2","key":"e_1_3_5_32_1","first-page":"220","article-title":"Oral nirmatrelvir\/ritonavir therapy for COVID-19: The dawn in the dark?","volume":"11","author":"Hung YP","year":"2022","unstructured":"Hung YP, , Lee JC, , Chiu CW, et al. Oral nirmatrelvir\/ritonavir therapy for COVID-19: The dawn in the dark?. Antibiot (Basel, Switzerland), 2022; 11(2):220; doi: 10.3390\/ANTIBIOTICS11020220","journal-title":"Antibiot (Basel, Switzerland)"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.137249"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0729"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0195fje"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2021-0252"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105933"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01378-w"},{"key":"e_1_3_5_40_1","author":"Lemaitre F","year":"2022","unstructured":"Lemaitre F, , Budde K, , Van Gelder T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19. Ther Drug Monit, 2022; doi: 10.1097\/FTD.0000000000001014","journal-title":"Ther Drug Monit"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.964204"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111536"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2646"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07639-1"},{"key":"e_1_3_5_45_1","author":"Najjar-Debbiny R","year":"2022","unstructured":"Najjar-Debbiny R, , Gronich N, , Weber G, et al. Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients. Clin Infect Dis, 2022; doi: 10.1093\/CID\/CIAC443","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2018.0114"},{"key":"e_1_3_5_47_1","unstructured":"NCBI. Home\u2014SNP\u2014NCBI. Available from: https:\/\/www.ncbi.nlm.nih.gov\/snp\/[Last accessed: November 29 2022]."},{"key":"e_1_3_5_48_1","unstructured":"NIH. Molnupiravir | COVID-19 Treatment Guidelines. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antiviral-therapy\/molnupiravir\/ [Last accessed: November 29 2022a]."},{"key":"e_1_3_5_49_1","unstructured":"NIH. SARS-CoV-2 Testing | COVID-19 Treatment Guidelines. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/sars-cov-2-testing\/ [Last accessed: November 29 2022b]."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0806-942"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-20"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122921"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.11.024"},{"key":"e_1_3_5_54_1","unstructured":"PharmGKB. PharmGKB. Available from: https:\/\/www.pharmgkb.org\/ [Last accessed: November 29 2022]."},{"key":"e_1_3_5_55_1","unstructured":"PharmVar. PharmVar. Available from: https:\/\/www.pharmvar.org\/ [Last accessed: November 29 2022]."},{"issue":"1","key":"e_1_3_5_56_1","doi-asserted-by":"crossref","first-page":"e5877","DOI":"10.25248\/reas.e5877.2021","article-title":"Remdesivir: A Efic\u00e1cia Da Nova Droga No Controle Do Coronav\u00edrus Da S\u00edndrome Respirat\u00f3ria Aguda Grave 2 (Sars-Cov-2) Recentemente Emergido","volume":"13","author":"Rios DL","year":"2021","unstructured":"Rios DL, , Andrade TA, , Costa SdS, et al. Remdesivir: A Efic\u00e1cia Da Nova Droga No Controle Do Coronav\u00edrus Da S\u00edndrome Respirat\u00f3ria Aguda Grave 2 (Sars-Cov-2) Recentemente Emergido. Rev Eletr\u00f4nica Acervo Sa\u00fade, 2021; 13(1):e5877\u2013e5877; doi: 10.25248\/REAS.E5877.2021","journal-title":"Rev Eletr\u00f4nica Acervo Sa\u00fade"},{"key":"e_1_3_5_57_1","author":"Saravolatz LD","year":"2022","unstructured":"Saravolatz LD, , Depcinski S, , Sharma M. Molnupiravir and nirmatrelvir-ritonavir: Oral COVID antiviral drugs. Clin Infect Dis, 2022; doi: 10.1093\/CID\/CIAC180","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.05.021"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01594"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2603"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11040326"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa239"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.069252"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13313"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00372-5"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-022-02265-9"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05752-1"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13167-021-00247-0"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"e_1_3_5_72_1","author":"Young C","year":"2022","unstructured":"Young C, , Papiro T, , Greenberg JH. Elevated tacrolimus levels after treatment with nirmatrelvir\/ritonavir (paxlovid) for COVID-19 infection in a child with a kidney transplant. Pediatr Nephrol, 2022; doi: 10.1007\/S00467-022-05712-0","journal-title":"Pediatr Nephrol"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-021-02841-3"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab247"}],"container-title":["OMICS: A Journal of Integrative Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/omi.2022.0151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/omi.2022.0151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/omi.2022.0151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:06:00Z","timestamp":1777676760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/omi.2022.0151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1089\/omi.2022.0151"],"URL":"https:\/\/doi.org\/10.1089\/omi.2022.0151","relation":{},"ISSN":["1536-2310","1557-8100"],"issn-type":[{"value":"1536-2310","type":"print"},{"value":"1557-8100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}